BRAIDWELL LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001920938

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2024 · 61 positions · Total reported value $2.48B · Top-10 concentration 38.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.0% · 24 new · 32 cut · 25 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +24.0% · vs SPY +9.2% · Prev Value $2.64B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, BRAIDWELL LP disclosed 61 equity positions with a combined reported value of $2.48B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 38.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were HSCS ($133.11M), NVCR ($124.63M), APGE ($122.44M). By sector, the heaviest allocations are Health Care 85.6%, Industrials 1.1%. Versus the prior quarter, allocation shifted toward Other (+1.2pp) and away from Industrials (-0.9pp).

Versus the prior quarter, BRAIDWELL LP opened 24 new positions, trimmed 32 and fully exited 25, a turnover rate of 75.0% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q1 2024 were VKTX ($58.47M), CGON ($49.62M), AVDL ($45.07M).

Of the 25 positions fully exited versus the prior quarter, the largest were ASND ($130.39M), TNDM ($67.18M), IMCR ($41.77M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • VKTX VIKING THERAPEUTICS INC · $58.47M
  • CGON CG ONCOLOGY INC · $49.62M
  • AVDL AVADEL PHARMACEUTICALS PLC · $45.07M
  • ISRG INTUITIVE SURGICAL INC · $40.11M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · $33.53M
  • RLAY RELAY THERAPEUTICS INC COM · $31.08M
  • KNSA KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A · $27.48M
  • LXEO LEXEO THERAPEUTICS INC COM · $20.73M

Fully Exited (vs previous quarter)

  • ASND ASCENDIS PHARMA A/S · prev qtr: $130.39M
  • TNDM TANDEM DIABETES · prev qtr: $67.18M
  • IMCR IMMUNOCORE HLDGS PLC · prev qtr: $41.77M
  • LNTH LANTHEUS HLDGS INC · prev qtr: $30.70M
  • AMGN AMGEN INC · prev qtr: $16.76M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $15.04M
  • THRD THIRD HARMONIC BIO INC · prev qtr: $14.44M
  • MRUS MERUS N V · prev qtr: $10.19M

Insider Transactions (Form 4)

Latest BRAIDWELL LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Braidwell LP, based in Stamford, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 83 positions worth $2.54B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: STAMFORD, CT, United States
  • SEC registration: 801-122966 (status: Approved), registered 2022-01-03
  • Regulatory AUM (Form ADV): $3.63B as of 2026-09-22
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 11 hedge funds
  • Website: braidwell.com

Portfolio Structure

  • 83 positions · $2.54B reported value (Q2 2026)
  • Top 10 holdings = 32.8% of reported value
  • Largest position: CAI (CARIS LIFE SCIENCES INC) at 5.8%
  • Average position size: $30.62M

Sector Tilt

  • Health Care 90.1%
  • Information Technology 4.3%
  • Industrials 4.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 24 new, 21 added, 32 reduced, 25 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 85.6%
Other 13.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 144.00M $133.11M 5.37%
5.37%
Add
2 135.83M $124.63M 5.03%
5.03%
Hold
3 1.84M $122.44M 4.94%
4.94%
Add
4 730.21K $100.71M 4.06%
4.06%
Add
5 219.82K $86.55M 3.49%
3.49%
Add
6 1.21M $82.84M 3.34%
3.34%
Reduce
7 103.58M $82.61M 3.33%
3.33%
Add
8 65.00M $71.59M 2.89%
2.89%
Add
9 1.24M $69.76M 2.81%
2.81%
Add
10 64.89M $69.43M 2.80%
2.80%
Add
11 66.00M $68.85M 2.78%
2.78%
Add
12 295.89K $66.04M 2.66%
2.66%
Add
13 7.22M $62.61M 2.53%
2.53%
Add
14 50.67M $59.31M 2.39%
2.39%
Hold
15 713.10K $58.47M 2.36%
2.36%
New
16 1.31M $56.31M 2.27%
2.27%
Reduce
17 483.26K $56.06M 2.26%
2.26%
Reduce
18 169.25K $55.50M 2.24%
2.24%
Add
19 2.48M $51.10M 2.06%
2.06%
Add
20 56.03M $49.65M 2.00%
2.00%
Add
21 1.13M $49.62M 2.00%
2.00%
New
22 737.38K $48.81M 1.97%
1.97%
Reduce
23 614.53K $45.44M 1.83%
1.83%
Add
24 2.67M $45.07M 1.82%
1.82%
New
25 450.68K $42.49M 1.71%
1.71%
Add
26 3.37M $41.57M 1.68%
1.68%
Hold
27 100.50K $40.11M 1.62%
1.62%
New
28 2.17M $35.91M 1.45%
1.45%
Reduce
29 65.98M $35.79M 1.44%
1.44%
Hold
30 1.05M $33.53M 1.35%
1.35%
New
31 1.11M $32.30M 1.30%
1.30%
Hold
32 177.09K $31.51M 1.27%
1.27%
Reduce
33 3.74M $31.08M 1.25%
1.25%
New
34 1.39M $27.48M 1.11%
1.11%
New
35 47.15K $27.40M 1.11%
1.11%
Reduce
36 142.84K $26.27M 1.06%
1.06%
Add
37 1.78M $25.65M 1.03%
1.03%
Hold
38 101.49K $21.80M 0.88%
0.88%
Reduce
39 1.24M $21.14M 0.85%
0.85%
Hold
40 906.82K $20.77M 0.84%
0.84%
Hold
41 1.32M $20.73M 0.84%
0.84%
New
42 20.00M $19.94M 0.80%
0.80%
Add
43 21.50M $19.85M 0.80%
0.80%
New
44 515.00K $19.53M 0.79%
0.79%
Hold
45 218.90K $19.12M 0.77%
0.77%
New
46 435.82K $18.68M 0.75%
0.75%
Add
47 3.38M $17.17M 0.69%
0.69%
Reduce
48 1.16M $15.85M 0.64%
0.64%
New
49 1.15M $14.81M 0.60%
0.60%
Reduce
50 2.38M $14.33M 0.58%
0.58%
Reduce

FAQ

What did BRAIDWELL LP buy in 2024-Q1?

In its 2024-Q1 13F filing, BRAIDWELL LP reported 61 equity positions worth $2.48B in aggregate; its largest disclosed positions were HSCS ($133.11M), NVCR ($124.63M), APGE ($122.44M).

How large is BRAIDWELL LP's portfolio?

BRAIDWELL LP reported $2.48B of long equity holdings across 61 positions as of 2024-Q1. Top-10 holdings account for 38.1% of reported value.

What is BRAIDWELL LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/braidwell/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →